NCT05909618View on ClinicalTrials.gov

Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 11, 2023

Primary Completion Date

July 30, 2028

Study Completion Date

July 30, 2030

Conditions
Advanced GlioblastomaMetastatic Melanoma in the Central Nervous SystemMGMT-Unmethylated Glioblastoma
Interventions
DRUG

Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]

5 mg/kg solution for injection

DRUG

Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO]

3 mg/mL solution for injection

Trial Locations (1)

Unknown

RECRUITING

Sheba medical center, Ramat Gan

All Listed Sponsors
collaborator

Prof. Ronit Satchi-Fainaro, Director, Cancer Biology Research Center, Tel Aviv University, Tel Aviv, Israel.

UNKNOWN

lead

Sheba Medical Center

OTHER_GOV

NCT05909618 - Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases | Biotech Hunter | Biotech Hunter